



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	324012	Children's Calci Care
ARTG entry for	Medicine Listed	
Sponsor	Herbs of Gold Pty Ltd	
Postal Address	PO Box 3143, KIRRAWEE, NSW, 2232 Australia	
ARTG Start Date	25/09/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Children's Calci Care

Product Type	Single Medicine Product	Effective Date	27/08/2022
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support healthy growth and development in children
Maintain/support general health and wellbeing in children
Maintain/support healthy teeth in children
Maintain/support bone health in children
Aids/assists healthy bone development/growth/building in children
Maintain/support bone mass/density/integrity in children
Maintain/support (state mineral) absorption in bones in children
Maintain/support bone strength in children
Help maintain/support bone mineralisation in children
Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life in children
Maintain/support muscle health in children
Maintain/support muscle function in children
Maintain/support muscle strength in children
Maintain/support absorption of dietary (state vitamin/mineral/nutrient) in children

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Public Summary



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, chewable

Route of Administration Oral

Visual Identification

Active Ingredients

calcium hydrogen phosphate dihydrate	860.59 mg
Equivalent: calcium	200 mg
colecalfiferol	.0075 mg
menaquinone 7	8.75 microgram

Other Ingredients (Excipients)

Acacia
citric acid
colloidal anhydrous silica
d-alpha-tocopherol
Flavour
fractionated coconut oil
hypromellose
liquid glucose
magnesium stearate
maltodextrin
mannitol
silicon dioxide
sodium ascorbate
Stevia rebaudiana
xylitol

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary